Richard Cutler

Richard Cutler is an experienced clinical science executive with a comprehensive background in translational medicine and clinical development. Currently serving as Vice President and Head of Clinical Science at Nurix Therapeutics since February 2025, Richard has held senior roles at notable companies including Kronos Bio, Nektar Therapeutics, and Puma Biotechnology. Contributions include oversight of clinical trials for innovative cancer therapies, pivotal involvement in the successful approval of Kyprolis, and representation at leading scientific conferences. Richard's expertise encompasses precision medicine approaches targeting solid tumors and a solid educational background with a Ph.D. in Cell and Molecular Biology from Northwestern University, alongside degrees from Loyola University Chicago and a certificate from San Francisco State University in Clinical Trials Design and Management.